Philips and Masimo introduce new, advanced monitoring capabilities
to Philips high acuity patient monitors
June 1, 2023
Amsterdam, the Netherlands and Irvine, California, U.S.
– Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in
health technology, and Masimo (NASDAQ: MASI), a global medical
technology company, today announced FDA clearance allowing the
activation of SedLine® Brain Function Monitoring, Regional Oximetry
(O3®), and CO2 measurements in Philips Patient Monitors –
IntelliVue MX750 and MX850. The latest extension of Masimo and
Philips’ ongoing collaboration will help enable clinicians to make
quick and informed decisions without the need for additional
monitoring equipment.
Integrating the SedLine, O3® and CO2 advanced Masimo
measurements into Philips high acuity IntelliVue® MX series
multi-parameter monitors can help clinicians assess and monitor
blood saturation in the brain (cerebral oxygenation), anesthetic
sedation, and patient respiratory performance with ease, all from
the same monitor. The data can also be shared between monitors.
These capabilities and metrics help care providers to act
decisively while also helping to lower cost of care by providing a
more holistic view of the patient from one system.
“Our work with Masimo has enabled us to forge new paths in
continuous monitoring,” said Christoph Pedain, General Manager,
Hospital Patient Monitoring at Philips. “We’re connecting data and
technologies to help arm care providers with the robust information
they need to make timely, informed care decisions for their
patients.”
“Combining our expertise in noninvasive monitoring and signal
processing technologies with Philips’ expertise in integrated
patient monitoring and therapy solutions is a win-win for patients
and clinicians alike," said Jon Coleman, President of Worldwide OEM
Sales and Global Health, Masimo. "We are proud that Philips has
chosen to make our innovative SedLine, O3, and NomoLine
technologies available to their customers. We look forward to
continuing our partnership with a focus on improving patient
outcomes and reducing the cost of care.”
Since establishing a partnership to improve patient care,
outcomes and safety in 2016, Philips and Masimo have already
introduced a variety of advanced monitoring capabilities to select
IntelliVue® MX-series multi-parameter monitors. Today’s
announcement reveals the expansion of O3 regional oximetry
capability to Philips’ latest, high acuity MX750 and MX850 patient
monitors, as well as the introduction of new SedLine Brain Function
Monitoring and CO2 measurement capabilities, adding versatility to
Philips’ already robust portfolio of patient monitoring solutions
that support clinical workflow, caregiver efficiencies, and
enhanced patient care. To learn more about Philips’ ongoing
collaboration with Masimo to deliver on the future of continuous
monitoring, visit www.philips.com/masimo.
For further information, please contact:
Meredith AmorosoPhilips Global Press OfficeTel. : +1
724-584-8991E-mail : meredith.amoroso@philips.com
About Royal PhilipsRoyal
Philips (NYSE: PHG, AEX: PHIA) is a leading health technology
company focused on improving people's health and well-being through
meaningful innovation. Philips’ patient- and people-centric
innovation leverages advanced technology and deep clinical and
consumer insights to deliver personal health solutions for
consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, ultrasound, image-guided therapy, monitoring
and enterprise informatics, as well as in personal health. Philips
generated 2022 sales of EUR 17.8 billion and employs approximately
74,000 employees with sales and services in more than 100
countries. News about Philips can be found at
www.philips.com/newscenter.
About MasimoMasimo (NASDAQ: MASI) is a global
medical technology company that develops and produces a wide array
of industry-leading monitoring technologies, including innovative
measurements, sensors, patient monitors, and automation and
connectivity solutions. In addition, Masimo Consumer Audio is home
to eight legendary audio brands, including Bowers & Wilkins,
Denon, Marantz, and Polk Audio. Our mission is to improve life,
improve patient outcomes, and reduce the cost of care. Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
introduced in 1995, has been shown in over 100 independent and
objective studies to outperform other pulse oximetry technologies.1
Masimo SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,2 improve CCHD screening in
newborns3 and, when used for continuous monitoring with Masimo
Patient SafetyNet™ in post-surgical wards, reduce rapid response
team activations, ICU transfers, and costs.4-7 Masimo SET® is
estimated to be used on more than 200 million patients in leading
hospitals and other healthcare settings around the world,8 and is
the primary pulse oximetry at 9 of the top 10 hospitals as ranked
in the 2022-23 U.S. News and World Report Best Hospitals Honor
Roll.9 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth
Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve
Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7®,
Radius PPG®, and Radius VSM™, portable devices like Rad-67®,
fingertip pulse oximeters like MightySat® Rx, and devices available
for use both in the hospital and at home, such as Rad-97®. Masimo
hospital and home automation and connectivity solutions are
centered around the Masimo Hospital Automation™ platform, and
include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo
ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing
portfolio of health and wellness solutions includes Radius Tº® and
the Masimo W1™ watch. Additional information about Masimo and its
products may be found at www.masimo.com. Published clinical
studies on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi, RPVi, and Radius VSM have not received FDA 510(k) clearance
and are not available for sale in the United States. The use of the
trademark Patient SafetyNet is under license from University
HealthSystem Consortium.
1. Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.2. Castillo
A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2 Technology.
Acta Paediatr. 2011 Feb;100(2):188-92.3. de-Wahl Granelli A et al.
Impact of pulse oximetry screening on the detection of duct
dependent congenital heart disease: a Swedish prospective screening
study in 39,821 newborns. BMJ. 2009;Jan 8;338.4. Taenzer A et al.
Impact of pulse oximetry surveillance on rescue events and
intensive care unit transfers: a before-and-after concurrence
study. Anesthesiology. 2010:112(2):282-287.5. Taenzer A et al.
Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012.6. McGrath
S et al. Surveillance Monitoring Management for General Care Units:
Strategy, Design, and Implementation. The Joint Commission Journal
on Quality and Patient Safety. 2016 Jul;42(7):293-302.7. McGrath S
et al. Inpatient Respiratory Arrest Associated With Sedative and
Analgesic Medications: Impact of Continuous Monitoring on Patient
Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI:
10.1097/PTS.0000000000000696.8. Estimate: Masimo data on
file.9. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
- Masimo CO2, O3 and Sedline measurements are now available on
Philips high acuity MX750 & MX850 IntelliVue monitors
- Philips patient monitors MX750 and MX850 in an operating
room
Koninklijke Philips NV (EU:PHIA)
Graphique Historique de l'Action
De Août 2023 à Sept 2023
Koninklijke Philips NV (EU:PHIA)
Graphique Historique de l'Action
De Sept 2022 à Sept 2023
